INTRODUCTION
============

In December 2019, an outbreak of severe acute respiratory syndrome (SARS) attributed to a new coronavirus, namely, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was identified in the Wuhan region of China ([@B01]-[@B03]). The disease caused by the virus, called coronavirus disease (COVID-19), is characterized by a flu-like syndrome, with symptoms such as fever, cough, myalgia, and gastrointestinal symptoms ([@B04]). Most cases are mild, some may be asymptomatic, but approximately 15% of patients have a more severe presentation, and approximately 5% are critical ([@B05]). The acute respiratory failure among critically ill patients with COVID-19 is unique in its presentation: difficult-to-treat hypoxemia, clotting disorders, renal failure, and changes in immunity and inflammatory phenomena ([@B06]-[@B08]) all pose challenges to the management of these patients.

The virus spread from China to Europe and then the Americas, causing more than 20 million cases and hundreds of thousands of deaths as of August 15^th^ ([@B09]). Brazil is one of the countries with the highest number of cases as well as deaths, and Sao Paulo is currently the state with highest number of cases in the country ([@B10]), with over 26,000 deaths by mid-August.

Reports of the most important risks factors and mortality rates have become available ([@B11]-[@B17]), but as Latin America emerges as the new hotspot of the pandemic, there are no epidemiological data on COVID-19 or any epidemic of this magnitude in low- and middle-income countries (LMICs) that could help predict the impact of the new disease on its health system. The burden of critical illness is higher in LMICs ([@B18]), and the mortality of patients on mechanical ventilation in Brazil is high ([@B19]). Given the differences in the age distribution of the population, intensive care unit (ICU) capacity, lower availability of diagnostic testing for the new virus, difficulties in the implementation of public measures to mitigate virus spread in highly populated cities, and delayed access to health care, the burden of COVID-19 tends to be higher in LMICs than in high-income countries (HIC).

Knowing the characteristics of critically ill patients with COVID-19 and their clinical outcomes in LMICs is extremely important to inform clinical decision-making and public health management in this setting. Therefore, we designed an observational study to describe the characteristics and outcomes of patients admitted to the ICUs of the largest public hospital in Sao Paulo during the peak of the COVID-19 pandemic in Brazil.

MATERIALS AND METHODS
=====================

Study design and location
-------------------------

This is a cohort study conducted at Hospital das Clínicas from University of Sao Paulo Medical School. It is the largest academic, tertiary, university-affiliated hospital in Brazil with 300 adult ICU beds dedicated exclusively to the care of COVID-19 patients during the peak of the pandemic in Sao Paulo.

The Research Ethics Committee of Hospital das Clínicas da Universidade de Sao Paulo approved the study protocol (number 31382620.0.0000.0068), and the study was registered in a public database (clinicaltrials.gov, NCT04378582). The requirement for informed consent was waived because of the observational nature of the study.

From March 13 to April 16, 200 previously functioning ICU beds were converted into COVID-19-dedicated ICU beds. In the following 45 days, operating rooms and several hospital wards were repurposed to accommodate 100 additional COVID-19-ICU beds. Physicians, nurses, and respiratory therapists were hired to constitute new ICU teams dedicated to patients occupying these additional beds. New staff were trained and distributed within experienced ICU teams.

The study is observational, and patient care was carried out following institutional protocols developed specifically for COVID-19 patients. The protocol recommends routine use of deep venous thrombosis prophylaxis and systemic antibiotics if bacterial coinfection is suspected. Specific drugs for treating SARS-CoV-2 were not recommended but could be administered at the discretion of the attending physician. The study also included specific protocols for the ventilatory management of respiratory failure and for sedation management throughout ICU stay. Other critical care standards were not changed during the pandemic.

Study population
----------------

We will include all consecutive adult patients with suspected or confirmed COVID-19 admitted to the ICUs between March 30 and June 30, 2020 with an expected ICU stay longer than 24 hours ([Figure 1](#f01){ref-type="fig"}). The only exclusion criterion is ICU stay shorter than 24 hours. Patients readmitted to the ICU during their hospital stay will be included in the study only at their first ICU admission. Patients will be classified as confirmed COVID-19, highly suspected COVID-19 without laboratory confirmation, and ruled-out COVID-19. Positive results on either an RT-PCR assay of nasal specimens, throat-swab specimens, or tracheal aspirate or a serologic (antibody) test will be used to confirm SARS-CoV-2 infection. Patients highly suspected of having an infection but with negative RT-PCR test results initially will be submitted to a second RT-PCR test and/or a serologic test after seven days of symptom onset. Patients with ruled-out SARS-CoV-2 infection will be transferred to another facility in the same institution and will be excluded from analysis.

Outcomes
--------

The main outcome is ICU survival at 28 days. Secondary outcomes include duration of mechanical ventilation, need for rescue therapies for severe hypoxemia, need for renal replacement therapy, ICU complications, and hospital survival at 60 days.

Data collection, management, and quality control
------------------------------------------------

Data will be collected prospectively from study approval (May 6) to August 30, 2020 and retrospectively from March 30 to May 5, 2020. Trained data collectors will retrieve patient information from the hospital electronic medical records, and at the bedside ([Figure 2](#f02){ref-type="fig"}). Study data will be collected and managed using a secure, web-based data collection platform (REDCap - Research Electronic Data Capture) ([@B20],[@B21]). Data collected include demographic information, race, initial symptoms, comorbidities, outpatient medications, simplified acute physiology score (SAPS 3) ([@B22],[@B23]), and laboratorial test results at admission ([Table 1](#t01){ref-type="table"} and [2](#t02){ref-type="table"}). We will also collect data on the Sequential Organ Failure Assessment score (SOFA) ([@B24]), need for oxygen support, mechanical ventilator parameters, use of specific interventions to treat SARS-CoV-2 infection, and decision to withhold or withdraw life support ([Table 3](#t03){ref-type="table"}). Patients will be followed up for 28 days, and data on exposures and outcomes, such as use of non-invasive ventilation, use of a high-flow nasal cannula, number of days on mechanical ventilation, need for renal replacement therapy, tracheostomy, occurrence of thromboembolic events, use of prone positioning or extracorporeal membrane oxygenation (ECMO) support, and ICU discharge status, will be collected ([Table 4](#t04){ref-type="table"}). We will follow up patients to register vital status at 60 days or at hospital discharge, whichever occurs first.

Quality control measures will include the use of REDCap-based structured data collection forms, training data collectors to ensure data completeness and consistency, and data management processes within the platform to deal with missing data, outliers, and data collection mistakes.

We will report study results in accordance to recommended guidelines for reporting observational studies, the Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) ([@B25]), and the guidance from Pulmonary, Critical Care and Sleep journals on causal inference and prediction research ([@B26],[@B27]).

Statistical analysis plan
-------------------------

A sample size of 300 patients was initially anticipated. As the epidemic in Sao Paulo grew fast, the hospital included new ICU beds, and we revised the anticipated sample size to 500 patients. Given that the study carries no risks for participants and that the requirement for informed consent was waived by the IRB, we intend to collect data on all patients with COVID-19 admitted to the ICUs during the study period, a sample possibly larger than the anticipated sample size. Such a large sample would suffice to allow identification of predictors of survival.

Categorical variables will be expressed as counts and percentages, and continuous variables, as mean (standard deviation) or median (interquartile range), as appropriate. All hypothesis tests will be two-tailed, with a significance level of 0.05, and they will be performed using the R software (R Core Team, 2016, Vienna, Austria). We will build Kaplan-Meier curves to estimate 28-days survival. ICU survival will be defined as the time interval between ICU admission and patient death from any cause or ICU discharge. Time will be censored at 28 days for patients who are still alive. Hospital survival will be defined as the time interval between ICU admission and patient death from any cause or hospital discharge. Patients discharged home will be considered alive at day 28. We will perform survival analysis using the Cox proportional hazards model censored at 28 days to identify the main risk factors for ICU survival beyond expected associations, such as age, comorbidity burden, and severity of disease at ICU admission. Variables identified *a priori* as clinically relevant ([Table 5](#t05){ref-type="table"}) and additional variables with a *p*-value \<0.20 in a univariate analysis will be evaluated as independent risk factors of poor prognosis in a multivariable Cox model. The order of inclusion of variables into Cox multivariable models will follow statistical significance criteria and clinical relevance. Alternative models will be chosen on the basis of information criteria and likelihood ratio-based tests. Wherever possible, continuous variables will be modeled to account for nonlinearity with splines or polynomials and avoiding dichotomization. Additivity will be addressed with interaction terms. The proportional hazards assumption will be tested using Schoenfeld residuals. We will use mixed models to analyze the impact of ventilatory variables collected during hospitalization on the main clinical outcomes. We will perform complete case analyses, without missing data. We will also perform a sensitivity analysis using multiple imputation.

DISCUSSION
==========

Our study will report characteristics and outcomes of all patients admitted to the ICU at the largest academic hospital in Brazil during the peak of the pandemic of COVID-19 in Sao Paulo. The hospital developed a preparedness plan that included grouping COVID-19 patients in a building dedicated exclusively for the care of these patients, creation of surge ICUs to increase ICU bed capacity, and hiring additional healthcare professionals to work exclusively in the COVID-19 ICUs. The actions were coordinated by a crisis committee composed of critical care specialists, pulmonologists, infectious disease specialists, nurses, respiratory specialists, pharmacists, engineers, and administrators, among others, who met daily to make shared decisions. Such an effort helped prevent shortage of personal protective equipment and important medications, facilitated the development of institutional protocols for patient care and infection control, and contributed to a rational distribution of limited resources with potential impact on patient outcomes ([@B28]). The results will allow for the assessment of clinical outcomes of critically ill patients that will be representative of a middle-income country in a highly strained environment caused by the pandemic. Overall healthcare inequity in the treatment of chronic comorbidities in the Brazilian healthcare system, delayed access to proper critical care, and heterogeneity in ICU within the hospital (surge *vs.* previously functioning ICUs) are some of the system-level characteristics that highlight the importance of this study to assess overall survival of COVID-19 patients in LMICs.

We will also be able to assess resource utilization beyond mechanical ventilation, such as renal replacement therapy and ICU length of stay, to characterize the burden of this surge of severe respiratory failure patients to our hospital and healthcare system. In the main manuscript, both characterization of the cohort and the risk factors for increased mortality will be assessed and compared to the current literature. Our main benchmark for ICU and hospital survival is the result published regularly by the Intensive Care National Audit & Research Centre (ICNARC), that is, 35%-45% hospital mortality among patients receiving mechanical ventilation ([@B29]), which represents the outcomes of a universal healthcare system in a HIC.

In addition, the study will provide answers to many ancillary research questions:

A.  Rate of use and success rate of non-invasive ventilation and high-flow nasal cannula use to treat respiratory failure and of commonly used strategies for refractory respiratory failure, including inhaled nitric oxide, prone positioning, and ECMO.

B.  Prediction models of hospital mortality specific for COVID-19.

C.  Characterization of subgroups of interest, such as oncologic and transplant patients.

D.  System-level research questions to compare outcomes and processes of care in "surge" ICUs and previously functioning ICUs, which would allow planning for future surges in critical care capacity.

In conclusion, we will be able to describe the characteristics and outcomes of a large sample of critically ill patients with COVID-19 admitted to a dedicated hospital in a LMIC, which could inform health policy and resource allocation and allow for many exploratory research questions to be answered.
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###### Baseline characteristics at ICU admission.

  Variable                                      All participants (n)
  --------------------------------------------- ----------------------
  Age, years                                    mean (SD)
  Race\*                                        
      White                                     No. (%)
      Black                                     No. (%)
      Brown                                     No. (%)
      Asian                                     No. (%)
      Indigenous                                No. (%)
      Other - not declared                      No. (%)
  Male sex                                      No. (%)
  Body-mass index (kg/m^2^)                     mean (SD)
  SAPS 3                                        mean (SD)
  SOFA                                          median (IQR)
  Charlson's comorbidities score                median (IQR)
  Comorbidities                                 No. (%)
      Asthma                                    No. (%)
      Chronic Obstructive pulmonary disease     No. (%)
      Cardiovascular disease                    No. (%)
      Hypertension                              No. (%)
      Diabetes                                  No. (%)
      Chronic kidney disease of any stage       No. (%)
      Cancer                                    No. (%)
      Other                                     No. (%)
  Symptoms                                      No. (%)
      Loss of smell or taste                    No. (%)
      Fatigue                                   No. (%)
      Headache                                  No. (%)
      Altered level of consciousness            No. (%)
      Rhinorrhea                                No. (%)
      Diarrhea                                  No. (%)
      Shortness of breath                       No. (%)
      Sore throat                               No. (%)
      Fever                                     No. (%)
      Myalgia                                   No. (%)
      Cough                                     No. (%)
  Duration of symptoms before admission, days   median (IQR)
  Treatment before ICU admission                No (%)
      Chloroquine or hydroxychloroquine         No (%)
      Systemic corticosteroids                  No (%)
      Azithromycin                              No (%)
      Other antibiotics                         No (%)

SAPS 3: Simplified acute physiology score; SOFA: Sequential Organ Failure Assessment score; \*The categories represent the Brazilian official race classification.

###### Laboratory findings at ICU admission.

  Variable                           patients (n)
  ---------------------------------- --------------
  Arterial lactate mg/dL             mean (SD)
  Aspartate aminotransferase - U/L   mean (SD)
  Alanine aminotransferase - U/L     mean (SD)
  Total bilirubin - mg/dL            mean (SD)
  Creatinine - mg/dL                 mean (SD)
  Creatine kinase - U/L              mean (SD)
  D-dimer - ng/mL                    mean (SD)
  Lactate dehydrogenase - U/L        mean (SD)
  Ferritin - ng/mL                   mean (SD)
  White blood cell count/mm^3^       mean (SD)
  Lymphocyte count/mm^3^             mean (SD)
  Platelet count/mm^3^               mean (SD)
  C-reactive protein - mg/L          mean (SD)

###### Patient management on day 1 after ICU admission.

  Variables                                              All patients (n)
  ------------------------------------------------------ ------------------
  Sedation                                               No. (%)
  Midazolam                                              No. (%)
  Propofol                                               No. (%)
  Fentanyl                                               No. (%)
  Dexmedetomidine                                        No. (%)
  Other                                                  No. (%)
  Respiratory support                                    
  Oxygen catheter or mask                                No. (%)
  High-flow nasal cannula                                No. (%)
  Non-invasive ventilation                               No. (%)
  Invasive mechanical ventilation                        No. (%)
  Parameters during invasive ventilation (n=XXX)         
  Tidal volume (mL)                                      mean (SD)
  Minute volume (L/min)                                  mean (SD)
  FIO~2~ (%)                                             mean (SD)
  PaO~2~/FIO~2~                                          mean (SD)
  PEEP (cmH~2~O)                                         mean (SD)
  Plateau pressure (cmH~2~O)                             mean (SD)
  Driving pressure (cmH~2~O))                            mean (SD)
  pH                                                     
  PaCO~2~ (mmHg)                                         mean (SD)
  Oxygen saturation (%)                                  mean (SD)
  Rescue therapies                                       No. (%)
      Prone position                                     No. (%)
      Neuromuscular blockade                             No. (%)
      Inhaled pulmonary vasodilators                     No. (%)
      Extracorporeal membrane oxygenation                No. (%)
      Recruitment maneuvers                              No. (%)
      PEEP titration by compliance or driving pressure   No. (%)
  Vasopressors                                           No. (%)
  Antibiotics                                            No. (%)
  COVID-19 specific treatment                            No. (%)
  Chloroquine or hydroxychloroquine                      No. (%)
  Dexamethasone                                          No. (%)
  Methylprednisolone                                     No. (%)
  Hydrocortisone                                         No. (%)
  Prednisone                                             No. (%)
  Azithromycin                                           No. (%)
  Lopinavir / ritonavir                                  No. (%)
  Tocilizumab                                            No. (%)
  Anticoagulation, No. (%)                               No. (%)
  Prophylactic dose                                      No. (%)
  Full anticoagulation                                   No. (%)
  Limitation of treatment                                No. (%)

FIO~2~: fraction of inspired oxygen; PaO~2~: arterial partial pressure of oxygen; PEEP: positive pressure at end expiration.

###### Clinical outcomes at ICU discharge.

  Variable                                                                 Patients
  ------------------------------------------------------------------------ --------------
  Resource utilization                                                     
      Invasive mechanical ventilation                                      No. (%)
      Prone positioning                                                    No. (%)
      Duration of Mechanical ventilation (days)                            Median (IQR)
      Use of NIV[\*](#TFN01t04){ref-type="table-fn"}                       No. (%)
      Use of high-flow nasal cannula[\*](#TFN01t04){ref-type="table-fn"}   No. (%)
      Need for vasopressors                                                No. (%)
      Renal replacement therapy                                            No. (%)
      Tracheostomy                                                         No. (%)
  Clinical complications during ICU stay                                   
      Delirium                                                             No. (%)
      Thrombotic phenomena                                                 No. (%)
      Ventilator-associated pneumonia                                      No. (%)
      Cardiac arrythmias                                                   No. (%)
  Clinical outcomes                                                        
      ICU length of stay (days)                                            Median (IQR)
      Hospital length of stay (days)                                       Median (IQR)
      ICU mortality                                                        No. (%)
      Hospital mortality                                                   No. (%)

\*To avoid intubation or before intubation.

###### Predictors of ICU survival at 28 days.

  Variable                                                            Survivors (n)   Non-survivors (n)   *p*-value[\*](#TFN01t05){ref-type="table-fn"}
  ------------------------------------------------------------------- --------------- ------------------- -----------------------------------------------
  Baseline characteristics                                                                                
      Age,                                                            mean (SD)       mean (SD)           
      Male sex                                                        No. (%)         No. (%)             
      Charlson's comorbidity score                                    Median (IQR)    Median (IQR)        
      Obesity                                                         No. (%)         No. (%)             
  Acuity variables at admission[\#](#TFN02t05){ref-type="table-fn"}                                       
      Need for vasopressors                                           No. (%)         No. (%)             
      Invasive mechanical ventilation                                 No. (%)         No. (%)             
      Glasgow coma scale                                              Median (IQR)    Median (IQR)        
      Creatinine (mg/dL)                                              mean (SD)       mean (SD)           
      Platelets                                                       mean (SD)       mean (SD)           
      Bilirubin (mg/dL)                                               mean (SD)       mean (SD)           
      pH                                                              mean (SD)       mean (SD)           
  SAPS 3                                                              mean (SD)       mean (SD)           
  SOFA day 1                                                          Median (IQR)    Median (IQR)        
  Disease characteristics                                                                                 
      Time from symptom onset to ICU admission                        Median (IQR)    Median (IQR)        
      Number of days of intubation before ICU admission               Median (IQR)    Median (IQR)        
  Other laboratorial results                                                                              
      D-dimer (ng/mL)                                                 mean (SD)       mean (SD)           
      Lactate dehydrogenase (U/L)                                     mean (SD)       mean (SD)           
      Lymphocyte count (cells/mm^3^)                                  mean (SD)       mean (SD)           
      Arterial lactate (mg/dL)                                        mean (SD)       mean (SD)           
      pH                                                              mean (SD)       mean (SD)           

\**p*-value will come from univariate Cox proportional hazards model.

^\#^During the first 24h of ICU stay.
